cct3833
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02437227)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase RAFINHIBITOR
RAF1 inhibitor
- SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cct3833
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02437227 | Phase 1 | Mar 1, 2015 | Royal Marsden Hospital NHS Trust, University of London, Wellcome Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1